Transcript Building Europe Knowledge: Towards the Seventh Framework

Building Europe Knowledge
Towards the Seventh
Framework Programme
2007-2013
European Commission
Research DG
Health Research Directorate
23 June 2005
R&D – European weaknesses
R&D intensity (% of GDP) (3)
Share of R&D financed by industry (%)
(2)
Researchers per thousand labour force (FTE) (3)
Share of world scientific publications (%)
(3)
Scientific publications per million population (3)
Share of world triadic patents (%)
(1)
Triadic patents per million population (1)
High-tech exports as a share of total manufacturing exports (%)
Share of world high-tech exports (%)
Note:
(1)
2000 data
(2)
2002 data
(2)
(3)
2003 data
(3)
EU-25
US
Japan
1.97
2.59
3.12
55.9
63.1
73.9
5.5
9.0
9.7
38.3
31.1
9.6
639
809
569
31.5
34.3
26.9
30.5
53.1
92.6
19.7
28.5
26.5
16.7
20.0
10.6
Research: filling the gap
Total expenditure on R&D, % of GDP
Barcelona Summit, 2001
3,2
3,0
Japan: 3.0
2,8
USA: 2.7
2,6
2,4
2,2
2,0
EU-15: 1.9
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
1,8
Research and economic development
2,5
● DK ● SE
R&D investment
2
1,5
● FI
1
●A
●F ●B
● IRL
● NL
0,5
● EU ● UK● DE
-2
-1,5
●P
-1
●E
-0,5
●I
0
-0,5
0
0,5
-1
● EL
-1,5
-2
Economic performance
1
1,5
Why research at European level?
 Pooling and leveraging resources
– Resources are pooled to achieve critical mass
– Leverage effect on private investments
– Interoperability and complementarity of big science
 Fostering human capacity and excellence in S&T
– Stimulate training and international mobility of researchers
– Improve S&T capabilities
– Stimulate competition in research
 Better integration of European R&D
– Create scientific base for pan-European policy challenges
– Encourage coordination of national policies
– Effective comparative research at EU-level
– Efficient dissemination of research results
FPs : significant impacts on S&T
and the economy
 Economic benefits. €1 (research) at European level ► € 4-7 (long-run,
econometric models). Enterprises participating in FP benefit of:
– reduced commercial risk
– increased turnover and profitability
– enhanced productivity and market share
 Innovative performance. Enterprises participating in FP:
– tend to be more innovative
– more likely to patent
– engage in innovative cooperation with other firms and universities
 Scientific performance:
– FP project ► up to 9 peer reviewed publications (international co-publications)
 Human resources development:
– Over 7000 proposals for Marie Curie in 2004, thousands of researchers have
participated in top trans-national teams, benefiting from training and knowledge sharing
Projected FP7 economic impacts
(by 2030, as compared to a business-as-usual scenario)
Discontinuing
the FP and no
national
compensation
Doubling
funding under
FP7, moderate
growth
thereafter
Doubling
funding under
FP7, rapid
growth
thereafter
- 0.84
+ 0.45
+ 0.96
- 1.31
+ 0.69
+ 1.66
Extra employment (#)
- 840,000
+ 418,000
+ 925,000
Extra jobs in research (#)
- 87,000
+ 40,000
+ 214,000
Increase in R&D Intensity (% of GDP)
- 0.089
+ 0.059
+ 0.228
Change in exports to outside Europe (%)
-1.92
+0.64
+1.57
Change in imports from outside Europe (%)
+ 1.43
- 0.27
- 0.88
Indicators
Extra GDP (%)
Extra GDP when taking account of increases
over time in the quality of products (%)
What’s new ?
Main new elements compared to FP6:




Annual budget doubled (EUR 5 billion ►10 billion)
Basic research (~ EUR 1,5 billion per year)
Simplification of procedures
Logistical and administrative tasks transferred to
external structures
Simplification of procedures
Measures proposed:








Rationalising the funding schemes – simpler set of funding instruments
Avoiding red-tape! Less bureaucratic and more user-friendly languages
Reducing number and size of documents
Reducing number of request to participants and light submission
procedure
Reducing a priori controls (i.e. controls before the project is approved)
Increasing autonomy of consortia
Streamlining the selection process
Exploring new modes of funding and simplifying the cost-based funding
system
More on
Simplification
Budgets of the EU
Framework Programmes
80
€ Billion
68.3
70
60
50
40
30
20
10
13.12
3.27
5.36
14.96
17.5
6.6
0
1984-1987 1987-1991 1990-1994 1994-1998 1998-2002 2002-2006 2007-2013
FP7 budget
(EUR billion, 2004 constant prices)
Euratom
4,193
JRC
1,617
Cooperation
39,134
Capacities
6,594
People
6,279
Ideas
10,447
FP7 2007 - 2013
Specific Programmes
Cooperation – Collaborative research
Ideas – Frontier Research
People – Human Potential
Capacities – Research Capacity
+
JRC (non-nuclear)
JRC (nuclear)
Euratom
Information
Society
Nano, Materials,
Production
Energy
Environment
Transport
Socio-economic
Research
Collaborative
Research
8.317
2.455
12.670
4.832
2.931
2.535
5.940
792
Space and
Security
Biotech, Food,
Agriculture
COOPERATION
Themes
Health
Framework Programmes 7:
Objectifs and activities
3.960 44.432
IDEAS
European Research Council
11.862
PEOPLE
Marie Curie Actions
7.129
Research
Infrastructures
CAPACITIES
3.961
Regions
Research for, and
International
of
Research Potential Science in Society
by, SMEs
Co-operation
Knowled
1.901
158
554
554
7.486
358
JRC (EC)
1.817
Total
(Cash prices)
72.726
Cooperation – Collaborative research
9 Thematic Priorities
1.
2.
3.
4.
5.
6.
7.
8.
9.
Health
Food, agriculture and biotechnology
Information and communication technologies
Nanosciences, nanotechnologies, materials and new production
technologies
Energy
Environment (including climate change)
Transport (including aeronautics)
Socio-economic sciences and the humanities
Security and space
+ Euratom: Fusion energy research, nuclear fission and radiation protection
Cooperation: Health Theme

Under each theme there will be sufficient flexibility to address both
Emerging needs and Unforeseen policy needs

Dissemination of knowledge and transfer of results will be supported
in all thematic areas

Support will be implemented across all themes through:
Collaborative research
(Collaborative projects; Networks of Excellence; Coordination/support actions)
Joint Technology Initiatives
Coordination of non-Community research programmes
(ERA-NET; ERA-NET+; Article 169)
International Cooperation
HEALTH COLLABORATIVE
RESEARCH
Objective:

Improving the health of European
citizens

Increasing the competitiveness of
European health-related industries
and businesses

Addressing global health issues
including emerging epidemics
HEALTH COLLABORATIVE
RESEARCH
Rationale for pan-European approaches(I):




Sequencing of human genome and recent
advances in post-genomics
 vast amounts of data
Translational research (translation of basic
discoveries in clinical applications)
 multidisciplinarity
Clinical research  international multi-centre trials
health policy-driven research  comparisons of
the national models & data
HEALTH COLLABORATIVE
RESEARCH
Rationale for pan-European approaches(II):

Strong EU-based biomedical and research 
to strenghten the competitiveness of large
industries (pharma) as well as SMEs
(healthcare biotech & medical technology/)
 Trans-national cooperation is essential to face the
worldwide competition
 This research will also contribute to the development
of new norms & standards to set up appropriate
legislative framework for new medical technologies
(e.g. regenerative medicine), which is essential for
industry
HEALTH COLLABORATIVE
RESEARCH
Activities  3 pillars

Biotechnology, generic tools and
technologies for human health

Translating research for human
health

Optimising the delivery of health
care to European citizens
HEALTH COLLABORATIVE
RESEARCH
Pillar 1  Biotechnology, generic tools and
technologies for human health

High-throughput research

Detection, diagnosis and monitoring.
Predicting suitability, safety and efficacy of
therapies (incl. alternatives to animal testing)

Innovative therapeutic approaches and
Intervention

HEALTH COLLABORATIVE
RESEARCH
Pillar 2  Translating research for human health
Integrating biological data and processes: large-scale
data gathering, systems biology


Research on the brain and related diseases, human
development and ageing

Translational research in infectious diseases (incl.
HIV/AIDS, malaria, tuberculosis, SARS, etc.)

Translational research in major diseases: cancer,
cardiovascular disease, diabetes/obesity; rare
diseases; and other chronic diseases (e.g.
osteoarthritis).
HEALTH COLLABORATIVE
RESEARCH
Pillar 3 Optimising the delivery of health care to
European citizens

Translating clinical outcome into clinical practice

Quality, efficiency and solidarity of health systems
including transitional health systems (i.e. health
systems that are currently under a reform process)

Enhanced disease prevention and better use of
medicines

Appropriate use of new health therapies and
technologies
HEALTH COLLABORATIVE
RESEARCH
2 other strategic issues that will be
addressed across activities:
Child health
 The health of the ageing population

HEALTH COLLABORATIVE
RESEARCH
From FP6 & FP7:
• Continuity in the research activities
• Focus on genomics has disappeared
• Emphasis put on translational research
• Biomedical technology & engineering (rich in
SMEs) is re-introduced
• health policy-driven research (public health) is
strongly reinforced
HEALTH COLLABORATIVE
RESEARCH
Indicative Budget:
€ 7.325 million (2004 prices)
 € 8.317 million (cash prices)

Joint Technology Initiative
 Innovative Medicines
Long term objective:
To increase the competitiveness of the European Pharmaceutical
industry, and to foster Europe as the most attractive place for
pharmaceutical R&D.
Thereby enhancing access of innovative medicines to the benefit
of patients and society.
Aim:
To remove major bottlenecks in the drug development process, as
identified by industry, and where research is the key.
Innovative Medicines Initiative
Industry (under the leadership of EFPIA) has
identified the bottlenecks in agreement with key
stakeholders: Academia, Regulatory agencies, Patient
organisations, Clinical researchers, Ethical experts,
etc.
A Strategic Research Agenda prioritising the
research needs and how they should be
implemented is being developed by panels of
experts. This process is driven by industry.
Innovative Medicines Initiative
The Strategic Research Agenda will address the
bottlenecks in four main areas:

Improved prediction – early indications of safety.

Improved clinical performance – early indications of efficacy
by use of biomarkers.

Better knowledge management through collaboration –
breaking information barriers at the interfaces.

Bridging educational gaps – pre-clinical and clinical research
and breaking barriers between disciplines.
http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed
http://www.cordis.lu/lifescihealth/innovativemedicines.htm
FP7 Timetable
6 April 2005
Commission’s proposal
September 2005 ?
Specific programmes’ proposal
December 2005 ?
First reading at EP
January 2006 ?
Common position at Council
March 2006 ?
Second reading and approval at EP
June 2006 ?
Adoption
November 2006 ?
Launch Conference / 1st calls for
proposals
Information

EU research: http://europa.eu.int/comm/research

Seventh Framework Programme:
http://europa.eu.int/comm/research/fp6/index_en.html

Information on research programmes and
projects:
http://www.cordis.lu

RTD info magazine:
http://europa.eu.int/comm/research/rtdinfo/

Information requests:
[email protected]